NIAID provides an array of services to assist investigators developing the following types of products:
- Therapies for the Treatment of HIV Disease
- Therapies for the Treatment of HIV-Associated Co-Infections
- Microbicides for the Prevention of HIV Transmission
These services are provided at no cost to the investigator and include evaluation of compounds in cell culture and animal models, chemical synthesis, analytical chemistry, drug formulation, and animal pharmacology and toxicology.
Investigators seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. These services are offered to fill specific gaps in an investigator’s drug development plan as they advance their product towards clinical investigation.
Investigators seeking access to these services must have a defined product of known chemical structure and must have preliminary data to support the continued development of that product. Investigators seeking the random screening of new compounds without any accompanying biological data are poor candidates for these services.
In addition, NIAID funds the Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) which provides access to a centralized group of subject matter experts, establishes a communications and data hub for dissemination of important results and resources, and develops a modeling and simulation core to aid investigators in assigning priority to drugs and formulations in development.